Progress of oncolytic viruses in sarcomas

Christina K. Lettieri, Pooja Hingorani, E. Anders Kolb

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Oncolytic virotherapy has shown exciting promise for the treatment of many types of solid tumors. Pediatric sarcomas are an aggressive type of pediatric malignancy known to show limited responsiveness to current therapies, leading to unacceptably high morbidity and mortality. Oncolytic viruses have only recently been used for the treatment of this challenging cancer, and results have been encouraging. Five clinical trials are currently open evaluating the use of oncolytic viruses in pediatric malignancies. Advances in genetic engineering of the viruses include improving the ability of the virus to infect tumor cells, engineering the virus with transgenes which improve the virus' ability to kill tumor cells and manipulating the virus to enhance concomitantly administered therapies. Further understanding of the antiviral immune response and a viral induced anti-tumor immune response will permit a maximization of oncolytic virotherapy.

Original languageEnglish (US)
Pages (from-to)229-242
Number of pages14
JournalExpert review of anticancer therapy
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Oncolytic Viruses
Sarcoma
Viruses
Oncolytic Virotherapy
Neoplasms
Pediatrics
Cell Engineering
Genetic Engineering
Therapeutics
Transgenes
Antiviral Agents
Clinical Trials
Morbidity
Mortality

Keywords

  • Seneca Valley virus
  • adenovirus
  • clinical trial
  • herpes simplex virus
  • oncolytic virus
  • pediatric sarcoma
  • reovirus
  • vesicular stomatitis virus

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Lettieri, C. K., Hingorani, P., & Kolb, E. A. (2012). Progress of oncolytic viruses in sarcomas. Expert review of anticancer therapy, 12(2), 229-242. https://doi.org/10.1586/era.11.205

Progress of oncolytic viruses in sarcomas. / Lettieri, Christina K.; Hingorani, Pooja; Kolb, E. Anders.

In: Expert review of anticancer therapy, Vol. 12, No. 2, 01.02.2012, p. 229-242.

Research output: Contribution to journalReview article

Lettieri, CK, Hingorani, P & Kolb, EA 2012, 'Progress of oncolytic viruses in sarcomas', Expert review of anticancer therapy, vol. 12, no. 2, pp. 229-242. https://doi.org/10.1586/era.11.205
Lettieri, Christina K. ; Hingorani, Pooja ; Kolb, E. Anders. / Progress of oncolytic viruses in sarcomas. In: Expert review of anticancer therapy. 2012 ; Vol. 12, No. 2. pp. 229-242.
@article{746fbfd46daa46e2a5b2ac5748bfb6c7,
title = "Progress of oncolytic viruses in sarcomas",
abstract = "Oncolytic virotherapy has shown exciting promise for the treatment of many types of solid tumors. Pediatric sarcomas are an aggressive type of pediatric malignancy known to show limited responsiveness to current therapies, leading to unacceptably high morbidity and mortality. Oncolytic viruses have only recently been used for the treatment of this challenging cancer, and results have been encouraging. Five clinical trials are currently open evaluating the use of oncolytic viruses in pediatric malignancies. Advances in genetic engineering of the viruses include improving the ability of the virus to infect tumor cells, engineering the virus with transgenes which improve the virus' ability to kill tumor cells and manipulating the virus to enhance concomitantly administered therapies. Further understanding of the antiviral immune response and a viral induced anti-tumor immune response will permit a maximization of oncolytic virotherapy.",
keywords = "Seneca Valley virus, adenovirus, clinical trial, herpes simplex virus, oncolytic virus, pediatric sarcoma, reovirus, vesicular stomatitis virus",
author = "Lettieri, {Christina K.} and Pooja Hingorani and Kolb, {E. Anders}",
year = "2012",
month = "2",
day = "1",
doi = "10.1586/era.11.205",
language = "English (US)",
volume = "12",
pages = "229--242",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Progress of oncolytic viruses in sarcomas

AU - Lettieri, Christina K.

AU - Hingorani, Pooja

AU - Kolb, E. Anders

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Oncolytic virotherapy has shown exciting promise for the treatment of many types of solid tumors. Pediatric sarcomas are an aggressive type of pediatric malignancy known to show limited responsiveness to current therapies, leading to unacceptably high morbidity and mortality. Oncolytic viruses have only recently been used for the treatment of this challenging cancer, and results have been encouraging. Five clinical trials are currently open evaluating the use of oncolytic viruses in pediatric malignancies. Advances in genetic engineering of the viruses include improving the ability of the virus to infect tumor cells, engineering the virus with transgenes which improve the virus' ability to kill tumor cells and manipulating the virus to enhance concomitantly administered therapies. Further understanding of the antiviral immune response and a viral induced anti-tumor immune response will permit a maximization of oncolytic virotherapy.

AB - Oncolytic virotherapy has shown exciting promise for the treatment of many types of solid tumors. Pediatric sarcomas are an aggressive type of pediatric malignancy known to show limited responsiveness to current therapies, leading to unacceptably high morbidity and mortality. Oncolytic viruses have only recently been used for the treatment of this challenging cancer, and results have been encouraging. Five clinical trials are currently open evaluating the use of oncolytic viruses in pediatric malignancies. Advances in genetic engineering of the viruses include improving the ability of the virus to infect tumor cells, engineering the virus with transgenes which improve the virus' ability to kill tumor cells and manipulating the virus to enhance concomitantly administered therapies. Further understanding of the antiviral immune response and a viral induced anti-tumor immune response will permit a maximization of oncolytic virotherapy.

KW - Seneca Valley virus

KW - adenovirus

KW - clinical trial

KW - herpes simplex virus

KW - oncolytic virus

KW - pediatric sarcoma

KW - reovirus

KW - vesicular stomatitis virus

UR - http://www.scopus.com/inward/record.url?scp=84856841169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856841169&partnerID=8YFLogxK

U2 - 10.1586/era.11.205

DO - 10.1586/era.11.205

M3 - Review article

C2 - 22316371

AN - SCOPUS:84856841169

VL - 12

SP - 229

EP - 242

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 2

ER -